Abstract

Retention of 18F-Flortaucipir is reportedly increased in the semantic variant of primary progressive aphasia (svPPA), which is dominated by TDP-43 pathology. However, it is unclear if 18F-Flortaucipir is also increased in other TDP-43 diseases, such as bvFTD caused by a C9orf72 gene mutation. We therefore recruited six C9orf72 expansion carriers, six svPPA patients, and 54 healthy controls. All underwent 18F-Flortaucipir PET and MRI scanning. Data from 39 Alzheimer’s Disease patients were used for comparison. PET tracer retention was assessed both at the region-of-interest (ROI) and at the voxel-level. Further, autoradiography using 3H-Flortaucipir was performed. SvPPA patients exhibited higher 18F-Flortaucipir retention in the lateral temporal cortex bilaterally according to ROI- and voxel-based analyses. In C9orf72 patients, 18F-Flortaucipir binding was slightly increased in the inferior frontal lobes in the ROI based analysis, but these results were not replicated in the voxel-based analysis. Autoradiography did not show specific binding in svPPA cases or in C9orf72-mutation carriers. In conclusion, temporal lobe 18F-Flortaucipir retention was observed in some cases of svPPA, but the uptake was of a lower magnitude compared to AD dementia. C9orf72-mutation carriers exhibited none or limited 18F-Flortaucipir retention, indicating that 18F-Flortaucipir binding in TDP-43 proteinopathies is not a general TDP-43 related phenomenon.

Details

Title
18F-Flortaucipir in TDP-43 associated frontotemporal dementia
Author
Smith, R 1   VIAFID ORCID Logo  ; Santillo, A F 2 ; Landqvist, Waldö M 3 ; Strandberg, O 2 ; Berron, D 2 ; Vestberg, S 4 ; van, Westen D 2   VIAFID ORCID Logo  ; van Swieten J 5 ; Honer, M 6 ; Hansson, O 7 

 Lund University, Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361); Skåne University Hospital, Department of Neurology, Lund, Sweden (GRID:grid.411843.b) (ISNI:0000 0004 0623 9987) 
 Lund University, Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361) 
 Clinical Sciences Helsingborg, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361) 
 Lund University, Department of Psychology, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361) 
 Erasmus Medical Centre, Department of Neurology, Rotterdam, The Netherlands (GRID:grid.5645.2) (ISNI:000000040459992X) 
 Roche Pharmaceutical Research and Early Development, Neuroscience Translational Technologies, Roche Innovation Center, Basel, Switzerland (GRID:grid.5645.2) 
 Lund University, Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361); Memory Clinic, Skåne University Hospital, Malmö, Sweden (GRID:grid.411843.b) (ISNI:0000 0004 0623 9987) 
Publication year
2019
Publication date
2019
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2210008436
Copyright
© The Author(s) 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.